Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuvisertib in myelofibrosis
NL-OMON59999Phase 2Not yet recruiting
- Sponsor
- Sumitomo Pharma America
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nuvisertib and mivavotinib in primary myelofibrosis (PMF) and secondary myelofibrosis (SMF) (2 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Dose-limiting toxicity, Adverse events and 1 more. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
nuvisertibmivavotinib
03
Conditions
primary myelofibrosis (PMF)secondary myelofibrosis (SMF)
Beyond the preview
Go deeper on NL-OMON59999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59999.